Mucosis is a clinical stage Dutch biotechnology company developing mucosal vaccines.
Mucosis B.V. is a clinical stage Dutch biotechnology company developing innovative mucosal vaccines that can be applied needle-free via the nose or mouth. Mucosis’s lead product candidate is SynGEM:registered:, an intranasal vaccine to prevent respiratory syncytial virus infection. Mucosis' vaccines are based on the patented and validated Mimopath:registered: technology. This technology enables a more natural immune response as well as a broad base of protection as was seen in their proof-of-concept animal and human studies of their FluGEM:registered: vaccine candidate.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 29, 2014 | Series Unknown | $6.90M | 1 | — | — | Detail |
Sep 10, 2007 | Series A | €3M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
MedSciences Capital | — | Series Unknown |